{"id":68017,"date":"2024-03-06T10:22:05","date_gmt":"2024-03-06T10:22:05","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/medigene-to-present-favorable-safety-profile-of-tcr-t-cells-upon-addition-of-costimulatory-switch-protein-with-a-poster-presentation-at-aacr-2024-annual-meeting\/"},"modified":"2024-03-06T10:22:05","modified_gmt":"2024-03-06T10:22:05","slug":"medigene-to-present-favorable-safety-profile-of-tcr-t-cells-upon-addition-of-costimulatory-switch-protein-with-a-poster-presentation-at-aacr-2024-annual-meeting","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/medigene-to-present-favorable-safety-profile-of-tcr-t-cells-upon-addition-of-costimulatory-switch-protein-with-a-poster-presentation-at-aacr-2024-annual-meeting\/","title":{"rendered":"Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting"},"content":{"rendered":"
\n

Planegg\/Martinsried, <\/b>March 6, 2024.<\/b> Medigene AG<\/u><\/a> (Medigene or the \u201cCompany\u201d, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the American Association for Cancer Research Annual Meeting (AACR) 2024 taking place from April 5-10, 2024 in San Diego, USA as well as an oral presentation at the ELRIG-Forum 2024 to be held in Darmstadt, Germany on March 7, 2024.<\/p>\n

Poster presentation:<\/b><\/p>\n

AACR 2024
<\/b>https:\/\/www.aacr.org\/meeting\/aacr-annual-meeting-2024\/<\/u><\/a>
<\/b>Location: San Diego Convention Center, San Diego
<\/b>Date: April 5-10, 2024<\/p>\n

Details on the poster presentation are as follows:<\/b><\/p>\n

Abstract title: TCR-gated control of costimulatory switch protein (CSP) activation in rTCR-T cells expressing PD1-41BB<\/b>
Maja Buerdek, Petra U. Prinz, Kathrin Mutze, Andrea Coluccio, Stefanie Tippmer, Miriam Bosch, Giulia Longinotti, Mario Catarinella, Kathrin Davari, Christiane Geiger, Barbara Loesch, Kristy Crame, Dolores J. Schendel.
Session details:<\/b> PO.IM01.13 – Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-T, Sunday, April 7, 1:30 PM – 5:00 PM local time<\/p>\n

The work to be presented shows that recombinant T cell receptor engineered T cells (rTCR-T cells), when armored and enhanced by the PD1-41BB CSP, exhibit superior TCR-T cell functionality and safety as well as a favorable safety profile, revealing the strong potential for improving treatment of cancer patients suffering from advanced solid tumor malignancies. <\/p>\n

The abstract for this research has been published online at https:\/\/www.abstractsonline.com\/pp8\/#!\/20272\/presentation\/6084<\/u><\/a> and the poster will be available online after the conference at https:\/\/medigene.com\/science\/abstracts\/<\/u><\/a>.<\/p>\n

The Company is planning a first-in-human trial for MDG1015, a TCR-T therapy incorporating the CSP in gastric cancer, ovarian cancer, myxoid\/round cell liposarcoma and synovial sarcoma with IND\/CTA filing targeted for 2H 2024. MDG1015 is a first-in-class, third generation TCR-T therapy targeting NY-ESO-1\/ LAGE-1a, armored and enhanced by the PD1-41BB CSP.<\/p>\n

Oral presentation:<\/b><\/p>\n

ELRIG-Forum 2024<\/b>
https:\/\/www.elrig.de\/index.php\/elrig-foren\/elrig-forum-2024<\/u><\/a>
Location: Darmstadtium Convention Centre, Darmstadt
<\/b>Date and time: March 7, 2024, 11:10 \u2013 11:30am local time
Presenter: Dr. Barbara L\u00f6sch, Head, Technology & Innovation
Title: Evolution by Innovation: Connecting the Dots of TCR-T Therapies<\/b><\/p>\n

Dr. L\u00f6sch will provide an overview on the Company\u2019s proprietary End-to-End (E2E) Platform and highlight various tools within the E2E Platform that can enhance TCR-T cell functionality, safety and efficacy for generation of best-in-class, differentiated TCR-T therapies. <\/p>\n

This presentation will available on Medigene\u2019s website on March 7, 2024: https:\/\/medigene.com\/science\/abstracts\/<\/u><\/a><\/p>\n

—\u00a0 end of press release\u00a0 —<\/i><\/p>\n

About Medigene AG<\/b><\/p>\n

Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing differentiated T cell therapies for treatment of solid tumors. Its End-to-End Platform is built on multiple proprietary and exclusive technologies that enable the Company to generate optimal T cell receptors against both cancer testis antigens and neoantigens, armor and enhance these T cell receptor engineered (TCR) -T cells to create best-in-class, differentiated TCR-T therapies, and optimize the drug product composition for safety, efficacy and durability. The End-to-End Platform provides product candidates for both its own therapeutics pipeline and partnering. Medigene\u2019s lead TCR-T program MDG1015 is expected to receive IND\/CTA approval in the second half of 2024. For more information, please visit https:\/\/medigene.com\/<\/u><\/a><\/p>\n

About Medigene\u2019s End-to-End Platform<\/b><\/p>\n

Medigene\u2019s immunotherapies help activate the patient\u2019s own defense mechanisms by harnessing T cells in the battle against cancer. Medigene\u2019s End-to-End Platform combines multiple exclusive and proprietary technologies to create best-in-class, differentiated TCR-T therapies. The platform includes multiple TCR generation and optimization technologies (e.g., Allogeneic-HLA (Allo-HLA) TCR Priming), as well as product enhancement technologies (e.g., PD1-41BB and CD40L-CD28 Costimulatory Switch Proteins, Precision Pairing) to address challenges in developing effective, durable and safe TCR-T therapies. Partnerships with multiple companies including BioNTech and 2seventy bio, continue to validate the platform\u2019s assets and technologies. <\/p>\n

About Medigene\u2019s PD1-41BB Costimulatory Switch Protein<\/b><\/p>\n

Checkpoint inhibition via PD-1\/PD-L1 pathway:<\/p>\n

Cells of solid tumors are sensitive to killing by activated T cells but can escape this killing activity by producing inhibitory molecules known as \u2018checkpoint proteins\u2019, such as the Programmed Death Ligand 1 (PD-L1), on their surface. When this occurs, activated T cells which express PD-1, the natural receptor for PD-L1, are inactivated. The expression of PD-L1 is an adaptive immune resistance mechanism for tumors that can help them survive and grow.<\/p>\n

The 4-1BB (CD137) costimulatory signaling pathway:<\/p>\n

Effective T cell immune responses to antigens typically require both a primary antigenic stimulation via the T cell receptor (TCR) and costimulatory signals. The intracellular signaling domains of the 4-1BB protein offer a well-characterized pathway to costimulation and enhanced T cell responses.<\/p>\n

Medigene\u2019s PD1-41BB switch receptor turns the tumor\u2019s attempted self-defense mechanism against the tumor by substituting the inhibitory signaling domain of PD-1 with the activating signaling domain of 4-1BB. Therefore, instead of inactivating T cells, the switch receptor delivers an activating signal to TCR-T cells. PD1-41BB-modified TCR-T cells proliferate strongly in the presence of PD-L1-positive tumor cells and kill more tumor cells upon repeated exposure. Additionally, switch receptor signals enable TCR-T cells to function better with low levels of glucose or high levels of TGF\u00df, two conditions characteristic of strongly hostile tumor microenvironments.<\/p>\n

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene\u00ae<\/sup> is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.<\/i><\/p>\n

Medigene AG<\/b><\/p>\n

Pamela Keck
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com<\/u><\/p>\n

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com<\/u><\/a>). We will then delete your address from our distribution list.<\/p>\n

\n <\/div>\n","protected":false},"excerpt":{"rendered":"

Planegg\/Martinsried, March 6, 2024. Medigene AG (Medigene or the \u201cCompany\u201d, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the American Association for Cancer Research Annual Meeting (AACR) 2024 taking place from April 5-10, 2024 in San Diego, […]<\/p>\n","protected":false},"author":2,"featured_media":68018,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/1464b205-f24e-4ae8-ab69-85968b38d774","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-68017","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/68017","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/comments?post=68017"}],"version-history":[{"count":0,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/68017\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media\/68018"}],"wp:attachment":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media?parent=68017"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/categories?post=68017"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/tags?post=68017"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}